Nivedita Arora1, Arjun Gupta, Navid Sadeghi. 1. aDepartment of Internal Medicine bDivision of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Abstract
PURPOSE OF REVIEW: To summarize the current epidemiology, management, and outcomes of primary effusion lymphoma (PEL) and highlight possible future research efforts. RECENT FINDINGS: Cyclophosphamide, doxorubicin, vincristine, prednisone-based chemotherapy regimens alone or in combination with immunomodulatory agents (e.g., lenalidomide), or proteasome inhibitors (e.g., bortezomib), or targeted therapies, are commonly used to treat PEL. Highly active antiretroviral therapy should be continued or initiated in patients with HIV infection. Randomized controlled trials are lacking. Prognosis remains grim and there exists a need for further investigation into optimal treatment strategies. SUMMARY: PEL is an aggressive mature B-cell neoplasm primarily seen in young to middle aged men with HIV, though immunosuppression related to age and comorbidities such as cirrhosis or organ transplantation also predisposes to PEL. Classic cavitary PEL presents as an effusion in the pleural, pericardial, or peritoneal space. Human herpes virus-8/Kaposi's sarcoma herpes virus) is classically detected. Given its rarity, randomized controlled trials evaluating optimal treatment regimens are lacking, and cyclophosphamide, doxorubicin, vincristine, prednisone-based chemotherapy has been the mainstay of treatment. Advancement in knowledge of the oncogenic signaling pathways involved in Kaposi's sarcoma herpes virus-induced tumorigenesis may pave the way to develop targeted therapies. VIDEO ABSTRACT.
PURPOSE OF REVIEW: To summarize the current epidemiology, management, and outcomes of primary effusion lymphoma (PEL) and highlight possible future research efforts. RECENT FINDINGS:Cyclophosphamide, doxorubicin, vincristine, prednisone-based chemotherapy regimens alone or in combination with immunomodulatory agents (e.g., lenalidomide), or proteasome inhibitors (e.g., bortezomib), or targeted therapies, are commonly used to treat PEL. Highly active antiretroviral therapy should be continued or initiated in patients with HIV infection. Randomized controlled trials are lacking. Prognosis remains grim and there exists a need for further investigation into optimal treatment strategies. SUMMARY: PEL is an aggressive mature B-cell neoplasm primarily seen in young to middle aged men with HIV, though immunosuppression related to age and comorbidities such as cirrhosis or organ transplantation also predisposes to PEL. Classic cavitary PEL presents as an effusion in the pleural, pericardial, or peritoneal space. Human herpes virus-8/Kaposi's sarcoma herpes virus) is classically detected. Given its rarity, randomized controlled trials evaluating optimal treatment regimens are lacking, and cyclophosphamide, doxorubicin, vincristine, prednisone-based chemotherapy has been the mainstay of treatment. Advancement in knowledge of the oncogenic signaling pathways involved in Kaposi's sarcoma herpes virus-induced tumorigenesis may pave the way to develop targeted therapies. VIDEO ABSTRACT.
Authors: Bal Mukunda Dhungel; Nathan D Montgomery; Matthew S Painschab; Maurice Mulenga; Tamiwe Tomoka; Bongani Kaimila; Takondwa Zuze; Edwards Kasonkanji; Coxcilly Kampani; Fred Chimzimu; Cara Randall; Robert Krysiak; Ryan Seguin; Yuri Fedoriw; Satish Gopal Journal: AIDS Date: 2018-09-24 Impact factor: 4.177
Authors: Eric S Pringle; Jaime Wertman; Nicole Melong; Andrew J Coombs; Andrew L Young; David O'Leary; Chansey Veinotte; Carolyn-Ann Robinson; Michael N Ha; Graham Dellaire; Todd E Druley; Craig McCormick; Jason N Berman Journal: Viruses Date: 2019-12-20 Impact factor: 5.048
Authors: Mark Manzano; Thomas Günther; Hyunwoo Ju; John Nicholas; Elizabeth T Bartom; Adam Grundhoff; Eva Gottwein Journal: mBio Date: 2020-08-25 Impact factor: 7.867